ORALLY ACTIVE MANNOSIDES SUBVERT ANTIBIOTIC RESISTANCE IF E COLI IN BLADDER

如果膀胱中有大肠杆菌，口服活性甘露糖苷可消除抗生素耐药性

• 批准号: 8361464
• 负责人: SCOTT J. HULTGREN
• 金额: $ 1.24万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8361464
• 关键词: Antibiotic Resistance; Bladder; Escherichia coli; Funding; Grant; Health; Mannosides; Mass Spectrum Analysis; Multi-Drug Resistance; National Center for Research Resources; Principal Investigator; Research; Research Infrastructure; Resistance to infection; Resources; Source; Trimethoprim-Sulfamethoxazole; United States National Institutes of Health; Urinary tract infection; Uropathogen; antimicrobial; biomedical resource; cost; pathogen

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Proliferation of antibiotic-resistant pathogens has been described as an impending health crisis1. This is increasingly evident for urinary tract infections (UTI) where resistance to first-line empiric therapy with trimethoprim-sulfamethoxazole (TMP-SMZ) by uropathogens complicates treatment, and drives use of alternate antimicrobial agents2. As a consequence, multidrug-resistant uropathogens are on the rise, making the straightforward treatment of UTI increasingly difficult.

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 抗生素耐药性病原体的增殖已被描述为即将来临的健康危机1。对于尿路感染（UTI），这是越来越明显的，在尿路感染对一线经验疗法的耐药性用甲甲苄酰磺胺甲氧唑（TMP-SMZ）通过尿道疾病的耐药性使治疗复杂化，并使使用替代抗菌药物的使用驱动器使用。 结果，多药抗性尿道病正在上升，这使得对UTI的直接治疗越来越困难。